BIOMAT Database Logo BIOMAT Database Logo

HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network. 1994

G J Gorse, and D H Schwartz, and B S Graham, and T J Matthews, and D M Stablein, and S E Frey, and R B Belshe, and M L Clements, and P F Wright, and M Eibl
Department of Internal Medicine, Saint Louis University School of Medicine, MO.

The purpose of this randomized, double-blind study was to test the safety and immunogenicity of an HIV-1LAI recombinant gp160 (rgp160) vaccine in healthy, uninfected volunteers using accelerated dosing schedules. Thirty volunteers were randomly assigned to receive 50-micrograms doses of rgp160 in one of two immunization schedules. Group 1 received rgp160 at times 0, 1, 2 and 5 months; and group 2 received rgp160 at times 0, 1, 2, 3 and 4 months. The vaccine was safe and stimulated high levels of HIV-1 envelope-specific binding antibody and T cell memory. There was a trend (P < 0.10) suggesting neutralizing antibodies were better induced by the regimen incorporating a rest period before the final immunization in group 1 volunteers. Both accelerated immunization schedules induced immune responses at levels similar to or better than those achieved by four rgp160 vaccine injections given over 12-18 months in other studies.

UI MeSH Term Description Entries
D007115 Immunization Schedule Schedule giving optimum times usually for primary and/or secondary immunization. Immunization Schedules,Schedule, Immunization,Schedules, Immunization
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011498 Protein Precursors Precursors, Protein
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

G J Gorse, and D H Schwartz, and B S Graham, and T J Matthews, and D M Stablein, and S E Frey, and R B Belshe, and M L Clements, and P F Wright, and M Eibl
HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network.
February 1995, Vaccine,
G J Gorse, and D H Schwartz, and B S Graham, and T J Matthews, and D M Stablein, and S E Frey, and R B Belshe, and M L Clements, and P F Wright, and M Eibl
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
April 1995, Pediatric AIDS and HIV infection,
G J Gorse, and D H Schwartz, and B S Graham, and T J Matthews, and D M Stablein, and S E Frey, and R B Belshe, and M L Clements, and P F Wright, and M Eibl
Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
November 1990, AIDS research and human retroviruses,
G J Gorse, and D H Schwartz, and B S Graham, and T J Matthews, and D M Stablein, and S E Frey, and R B Belshe, and M L Clements, and P F Wright, and M Eibl
Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.
November 1992, Journal of clinical immunology,
G J Gorse, and D H Schwartz, and B S Graham, and T J Matthews, and D M Stablein, and S E Frey, and R B Belshe, and M L Clements, and P F Wright, and M Eibl
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.
January 1991, Annals of internal medicine,
G J Gorse, and D H Schwartz, and B S Graham, and T J Matthews, and D M Stablein, and S E Frey, and R B Belshe, and M L Clements, and P F Wright, and M Eibl
Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network.
January 1992, Vaccine,
G J Gorse, and D H Schwartz, and B S Graham, and T J Matthews, and D M Stablein, and S E Frey, and R B Belshe, and M L Clements, and P F Wright, and M Eibl
Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network.
September 1995, Vaccine,
G J Gorse, and D H Schwartz, and B S Graham, and T J Matthews, and D M Stablein, and S E Frey, and R B Belshe, and M L Clements, and P F Wright, and M Eibl
Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
August 1994, JAMA,
G J Gorse, and D H Schwartz, and B S Graham, and T J Matthews, and D M Stablein, and S E Frey, and R B Belshe, and M L Clements, and P F Wright, and M Eibl
Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.
August 1994, Vaccine,
G J Gorse, and D H Schwartz, and B S Graham, and T J Matthews, and D M Stablein, and S E Frey, and R B Belshe, and M L Clements, and P F Wright, and M Eibl
NIAID will fund HIV vaccine trials network.
August 2000, American family physician,
Copied contents to your clipboard!